Need help finding what you are looking for?
Contact Us
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1424963
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1424963
Transplant Diagnostics Market Size and Share Analysis by Technology, Offering, Transplant Type, Application, End User - Global Industry Demand Forecast to 2030
PUBLISHED:
PAGES: 340 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
The transplant diagnostics market was valued at USD 4,686.7 million in 2023, and it will grow at a rate of 7.5% by the end of this decade, to touch USD 7,713.5 million by 2030.
This is attributable to the growing requirement for organ replacement procedures, the growing requirement for diagnostic procedures before organ replacement, and the powering occurrence of communicable diseases.
Also, the number of people with final-stage organ failure is on the rise, and because of the development in organ transplantation procedures, a high number of patients can now access these surgeries.
On the basis of technology, molecular assay led the industry with a share, of 65%, in 2023, and it will continue to dominate in the future as well.
This is due to the fact that molecular assays are extensively used in presurgical diagnostic processes for testing the compatibility of a recipient and donor. These assays are mostly accepted because of their tech benefits as opposed to non-molecular assays, for example the study of numerous samples and instantaneous analysis and high procedural efficacy.
The software & services category will grow the fastest in the future. This is because of the regular updates in software and enhanced services provided by the market players remain in the competition.
Furthermore, the expansion of more progressive instruments has led to a surge in the demand for training sessions to teach technical employees to handle and use an instrument. These factors led to the evolution of the industry.
The diagnostics category dominated the transplant diagnostics market, with a share of 70%, in 2023, and it will continue like this in the future. This is credited to the increasing occurrence of ailments.
Furthermore, the diagnostic category is divided into pre-transplantation and post-transplantation diagnostic. Additionally, for transplant processes, all relative diagnostic tests will be done prior to the transplant to see the compatibility of the transplant for example blood profiling, histocompatibility testing, and communicable disease testing.
North America had the largest share, of 50%, in 2023, and it will continue like this in the future. This has a lot to do with the high acceptance rate of cutting-edge techniques and analytic tools, high healthcare spending, the obtainability of skilled experts, and the extensive use of soft tissue transplants, stem cell therapies, and tailored medications.
Furthermore, the growing count of organ replacements, the increasing consciousness of transplantation, the growing incidence of communicable ailments, and the rising elderly populace susceptible to chronic ailments are powering the industry.
There is an increasing number of organ transplants happening around the world, and this will power the demand for transplant diagnostic solutions. The trend will continue in the years to come as well.
Top Providers of Transplant Diagnostics Are:
bioMerieux S.A.
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
Abbott Laboratories
Hologic Inc.
F. Hoffmann-La Roche Ltd.
Laboratory Corporation of America Holdings
BAG Diagnostics GmbH
Illumina Inc.
Product Code: 11958
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by technology
- 1.4.2. Market size breakdown, by offering
- 1.4.3. Market size breakdown, by transplant type
- 1.4.4. Market size breakdown, by end user
- 1.4.5. Market size breakdown, by application
- 1.4.6. Market size breakdown, by region
- 1.4.7. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Technology (2017-2030)
- 6.2.1. Molecular assay market revenue, by type (2017-2030)
- 6.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 6.3. Market Revenue, by Offering (2017-2030)
- 6.4. Market Revenue, by Transplant Type (2017-2030)
- 6.4.1. Solid organ market revenue, by type (2017-2030)
- 6.5. Market Revenue, by Application (2017-2030)
- 6.6. Market Revenue, by End User (2017-2030)
- 6.7. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Technology (2017-2030)
- 7.2.1. Molecular assay market revenue, by type (2017-2030)
- 7.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 7.3. Market Revenue, by Offering (2017-2030)
- 7.4. Market Revenue, by Transplant Type (2017-2030)
- 7.4.1. Solid organ market revenue, by type (2017-2030)
- 7.5. Market Revenue, by Application (2017-2030)
- 7.6. Market Revenue, by End User (2017-2030)
- 7.7. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Technology (2017-2030)
- 8.2.1. Molecular assay market revenue, by type (2017-2030)
- 8.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 8.3. Market Revenue, by Offering (2017-2030)
- 8.4. Market Revenue, by Transplant Type (2017-2030)
- 8.4.1. Solid organ market revenue, by type (2017-2030)
- 8.5. Market Revenue, by Application (2017-2030)
- 8.6. Market Revenue, by End User (2017-2030)
- 8.7. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Technology (2017-2030)
- 9.2.1. Molecular assay market revenue, by type (2017-2030)
- 9.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 9.3. Market Revenue, by Offering (2017-2030)
- 9.4. Market Revenue, by Transplant Type (2017-2030)
- 9.4.1. Solid organ market revenue, by type (2017-2030)
- 9.5. Market Revenue, by Application (2017-2030)
- 9.6. Market Revenue, by End User (2017-2030)
- 9.7. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Technology (2017-2030)
- 10.2.1. Molecular assay market revenue, by type (2017-2030)
- 10.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 10.3. Market Revenue, by Offering (2017-2030)
- 10.4. Market Revenue, by Transplant Type (2017-2030)
- 10.4.1. Solid organ market revenue, by type (2017-2030)
- 10.5. Market Revenue, by Application (2017-2030)
- 10.6. Market Revenue, by End User (2017-2030)
- 10.7. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Technology (2017-2030)
- 11.2.1. Molecular assay market revenue, by type (2017-2030)
- 11.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 11.3. Market Revenue, by Offering (2017-2030)
- 11.4. Market Revenue, by Transplant Type (2017-2030)
- 11.4.1. Solid organ market revenue, by type (2017-2030)
- 11.5. Market Revenue, by Application (2017-2030)
- 11.6. Market Revenue, by End User (2017-2030)
- 11.7. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Technology (2017-2030)
- 12.2.1. Molecular assay market revenue, by type (2017-2030)
- 12.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 12.3. Market Revenue, by Offering (2017-2030)
- 12.4. Market Revenue, by Transplant Type (2017-2030)
- 12.4.1. Solid organ market revenue, by type (2017-2030)
- 12.5. Market Revenue, by Application (2017-2030)
- 12.6. Market Revenue, by End User (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Technology (2017-2030)
- 13.2.1. Molecular assay market revenue, by type (2017-2030)
- 13.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 13.3. Market Revenue, by Offering (2017-2030)
- 13.4. Market Revenue, by Transplant Type (2017-2030)
- 13.4.1. Solid organ market revenue, by type (2017-2030)
- 13.5. Market Revenue, by Application (2017-2030)
- 13.6. Market Revenue, by End User (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Technology (2017-2030)
- 14.2.1. Molecular assay market revenue, by type (2017-2030)
- 14.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 14.3. Market Revenue, by Offering (2017-2030)
- 14.4. Market Revenue, by Transplant Type (2017-2030)
- 14.4.1. Solid organ market revenue, by type (2017-2030)
- 14.5. Market Revenue, by Application (2017-2030)
- 14.6. Market Revenue, by End User (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Technology (2017-2030)
- 15.2.1. Molecular assay market revenue, by type (2017-2030)
- 15.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 15.3. Market Revenue, by Offering (2017-2030)
- 15.4. Market Revenue, by Transplant Type (2017-2030)
- 15.4.1. Solid organ market revenue, by type (2017-2030)
- 15.5. Market Revenue, by Application (2017-2030)
- 15.6. Market Revenue, by End User (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Technology (2017-2030)
- 16.2.1. Molecular assay market revenue, by type (2017-2030)
- 16.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 16.3. Market Revenue, by Offering (2017-2030)
- 16.4. Market Revenue, by Transplant Type (2017-2030)
- 16.4.1. Solid organ market revenue, by type (2017-2030)
- 16.5. Market Revenue, by Application (2017-2030)
- 16.6. Market Revenue, by End User (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Technology (2017-2030)
- 17.2.1. Molecular assay market revenue, by type (2017-2030)
- 17.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 17.3. Market Revenue, by Offering (2017-2030)
- 17.4. Market Revenue, by Transplant Type (2017-2030)
- 17.4.1. Solid organ market revenue, by type (2017-2030)
- 17.5. Market Revenue, by Application (2017-2030)
- 17.6. Market Revenue, by End User (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Technology (2017-2030)
- 18.2.1. Molecular assay market revenue, by type (2017-2030)
- 18.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 18.3. Market Revenue, by Offering (2017-2030)
- 18.4. Market Revenue, by Transplant Type (2017-2030)
- 18.4.1. Solid organ market revenue, by type (2017-2030)
- 18.5. Market Revenue, by Application (2017-2030)
- 18.6. Market Revenue, by End User (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Technology (2017-2030)
- 19.2.1. Molecular assay market revenue, by type (2017-2030)
- 19.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 19.3. Market Revenue, by Offering (2017-2030)
- 19.4. Market Revenue, by Transplant Type (2017-2030)
- 19.4.1. Solid organ market revenue, by type (2017-2030)
- 19.5. Market Revenue, by Application (2017-2030)
- 19.6. Market Revenue, by End User (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Technology (2017-2030)
- 20.2.1. Molecular assay market revenue, by type (2017-2030)
- 20.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 20.3. Market Revenue, by Offering (2017-2030)
- 20.4. Market Revenue, by Transplant Type (2017-2030)
- 20.4.1. Solid organ market revenue, by type (2017-2030)
- 20.5. Market Revenue, by Application (2017-2030)
- 20.6. Market Revenue, by End User (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Technology (2017-2030)
- 21.2.1. Molecular assay market revenue, by type (2017-2030)
- 21.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 21.3. Market Revenue, by Offering (2017-2030)
- 21.4. Market Revenue, by Transplant Type (2017-2030)
- 21.4.1. Solid organ market revenue, by type (2017-2030)
- 21.5. Market Revenue, by Application (2017-2030)
- 21.6. Market Revenue, by End User (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Technology (2017-2030)
- 22.2.1. Molecular assay market revenue, by type (2017-2030)
- 22.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 22.3. Market Revenue, by Offering (2017-2030)
- 22.4. Market Revenue, by Transplant Type (2017-2030)
- 22.4.1. Solid organ market revenue, by type (2017-2030)
- 22.5. Market Revenue, by Application (2017-2030)
- 22.6. Market Revenue, by End User (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Technology (2017-2030)
- 23.2.1. Molecular assay market revenue, by type (2017-2030)
- 23.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 23.3. Market Revenue, by Offering (2017-2030)
- 23.4. Market Revenue, by Transplant Type (2017-2030)
- 23.4.1. Solid organ market revenue, by type (2017-2030)
- 23.5. Market Revenue, by Application (2017-2030)
- 23.6. Market Revenue, by End User (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Technology (2017-2030)
- 24.2.1. Molecular assay market revenue, by type (2017-2030)
- 24.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 24.3. Market Revenue, by Offering (2017-2030)
- 24.4. Market Revenue, by Transplant Type (2017-2030)
- 24.4.1. Solid organ market revenue, by type (2017-2030)
- 24.5. Market Revenue, by Application (2017-2030)
- 24.6. Market Revenue, by End User (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Technology (2017-2030)
- 25.2.1. Molecular assay market revenue, by type (2017-2030)
- 25.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 25.3. Market Revenue, by Offering (2017-2030)
- 25.4. Market Revenue, by Transplant Type (2017-2030)
- 25.4.1. Solid organ market revenue, by type (2017-2030)
- 25.5. Market Revenue, by Application (2017-2030)
- 25.6. Market Revenue, by End User (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Technology (2017-2030)
- 26.2.1. Molecular assay market revenue, by type (2017-2030)
- 26.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 26.3. Market Revenue, by Offering (2017-2030)
- 26.4. Market Revenue, by Transplant Type (2017-2030)
- 26.4.1. Solid organ market revenue, by type (2017-2030)
- 26.5. Market Revenue, by Application (2017-2030)
- 26.6. Market Revenue, by End User (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Technology (2017-2030)
- 27.2.1. Molecular assay market revenue, by type (2017-2030)
- 27.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 27.3. Market Revenue, by Offering (2017-2030)
- 27.4. Market Revenue, by Transplant Type (2017-2030)
- 27.4.1. Solid organ market revenue, by type (2017-2030)
- 27.5. Market Revenue, by Application (2017-2030)
- 27.6. Market Revenue, by End User (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Technology (2017-2030)
- 28.2.1. Molecular assay market revenue, by type (2017-2030)
- 28.2.2. Non-molecular assay market revenue, by type (2017-2030)
- 28.3. Market Revenue, by Offering (2017-2030)
- 28.4. Market Revenue, by Transplant Type (2017-2030)
- 28.4.1. Solid organ market revenue, by type (2017-2030)
- 28.5. Market Revenue, by Application (2017-2030)
- 28.6. Market Revenue, by End User (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. bioMerieux S.A.
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. Thermo Fisher Scientific Inc.
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Bio-Rad Laboratories Inc.
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. Abbott Laboratories
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. Hologic Inc.
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. F. Hoffmann-La Roche Ltd.
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. Laboratory Corporation of America Holdings
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. BAG Diagnostics GmbH
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
- 30.9. Illumina Inc.
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.